AGLE
Spyre Therapeutics Inc
$12.01
Earnings Summary
Revenue | $0Mn |
Net Profits | $-40.11Mn |
Net Profit Margins | -Inf% |
Highlights
Spyre Therapeutics Inc’s revenue fell -100% since last year same period to $0Mn in the Q3 2023. On a quarterly growth basis, Spyre Therapeutics Inc has generated -100% fall in its revenue since last 3-months.
Spyre Therapeutics Inc’s net profit fell -119.96% since last year same period to $-40.11Mn in the Q3 2023. On a quarterly growth basis, Spyre Therapeutics Inc has generated 81.52% jump in its net profits since last 3-months.
Spyre Therapeutics Inc’s net profit margin fell -Inf% since last year same period to -Inf% in the Q3 2023. On a quarterly growth basis, Spyre Therapeutics Inc has generated -Inf% fall in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Spyre Therapeutics Inc post its latest quarter earnings
EPS Estimate Current Quarter | -0.91 |
EPS Estimate Current Year | -0.91 |
Highlights
Spyre Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.91 - a -8.33% fall from last quarter’s estimates.
Spyre Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.91.
Key Ratios
Key ratios of the Spyre Therapeutics Inc post its Q3 2023 earnings
Earning Per Share (EPS) | -9.34 |
Highlights
Spyre Therapeutics Inc’s earning per share (EPS) fell -4815.79% since last year same period to -9.34 in the Q3 2023. This indicates that the Spyre Therapeutics Inc has generated -4815.79% annual rate of fall in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2023-11-09 | -0.84 | -9.34 | -1011.9% |
2023-08-11 | -0.18 | -1.66 | -822.22% |
2023-05-11 | -0.18 | -0.2 | -11.11% |
₹0 US Stocks a/c Opening Fee